Sarcopenia
Welcome,         Profile    Billing    Logout  
 46 Companies   12 Products   12 Products   17 Mechanisms of Action   756 Trials   22406 News 


«12...3334353637383940414243...401402»
  • ||||||||||  Journal:  Plasma C-terminal agrin fragment concentrations across adulthood: Reference values and associations with skeletal muscle health. (Pubmed Central) -  Aug 1, 2024   
    Our findings add clarity to existing data, demonstrating a robust relationship between circulating CAF and skeletal muscle integrity in the largest adult cohort to date, and support the use of CAF as an accessible, cost-effective screening tool for sarcopenia. However, further research into the prognostic utility of plasma CAF, and the establishment of normative data from other populations, are urgently needed if routine CAF screening is to be embedded into public healthcare settings.
  • ||||||||||  Xiaflex (collagenase clostridium histolyticum) / Asahi Kasei, SOBI, Endo
    Journal:  Systematic druggable genome-wide Mendelian randomization identifies therapeutic targets for sarcopenia. (Pubmed Central) -  Aug 1, 2024   
    Progressive and accelerated neurogenic sarcopenia may precede and potentially predict cognitive deficits observed in AD. Our research indicated MAP 3K3, MFGE8, COL15A1, HP, and HLA-DRA may serve as promising targets for sarcopenia, while the effectiveness of zinc supplementation and collagenase clostridium histolyticum for sarcopenia requires further validation.
  • ||||||||||  Trial completion:  Dietary Protein Quality for Skeletal Muscle Anabolism in Older Adults (clinicaltrials.gov) -  Aug 1, 2024   
    P=N/A,  N=30, Completed, 
    This knowledge is also timely for implementing comprehensive disease management strategies addressing multi-organ involvement in MASH pathogenesis. Recruiting --> Completed
  • ||||||||||  chloroquine phosphate / Generic mfg.
    EFFECT OF HDAC9/FNDC5/IRISIN-MEDIATED MITOPHAGY PATHWAY IN REGULATING SATELLITE CELL DIFFERENTIATION IN CIGARETTE SMOKE-INDUCED SKELETAL MUSCLE ATROPHY (Convention Center Exhibit Hall: Poster Area 3) -  Jul 31, 2024 - Abstract #CHEST2024CHEST_3895;    
    Inhibiting HDAC9 can lead to an increase in irisin expression and mitophagy levels, which in turn promote satellite cell differentiation and inhibit oxidative stress and skeletal muscle dysfunction in COPD mice. CLINICAL IMPLICATIONS: Patients with COPD with sarcopenia may benefit from clinical drugs related to the HDAC9/FNDC5/irisin-mediated mitophagy pathway, which has potential as a therapeutic target for their skeletal muscle dysfunction and atrophy.
  • ||||||||||  7809: Pulmonary Vascular Disease Section: Frailty in Pulmonary Hypertension (Convention Center Exhibit Hall: Experience CHEST) -  Jul 31, 2024 - Abstract #CHEST2024CHEST_3086;    
    Description: There is an increasing recognition of the impact of frailty and sarcopenia in outcomes of chronic lung disease, but its application in the clinical space it difficult. In this session, we will discuss some background evidence for frailty in pulmonary hypertension (PH), some common tools that may be used in clinical practice and tools that may be used as measures in clinical research studies.
  • ||||||||||  Review, Journal:  Vitamin D and Muscle Status in Inflammatory and Autoimmune Rheumatic Diseases: An Update. (Pubmed Central) -  Jul 31, 2024   
    Altered serum vitamin D status is commonly observed in inflammatory and autoimmune rheumatic diseases and seems to be associated with adverse muscle health outcomes. While maintaining adequate serum vitamin D concentrations may confer muscle-protective effects, further research is needed to confirm these findings and establish optimal supplementation strategies to obtain a safe and efficient serum threshold.
  • ||||||||||  Journal:  Functional Foods and Adapted Physical Activity as New Adjuvant Therapy for Chronic Kidney Disease Patients. (Pubmed Central) -  Jul 31, 2024   
    While maintaining adequate serum vitamin D concentrations may confer muscle-protective effects, further research is needed to confirm these findings and establish optimal supplementation strategies to obtain a safe and efficient serum threshold. The combination of FFs and APA can help counteract several CKD-related comorbidities, such as arterial hypertension, dyslipidemia and uremic sarcopenia, and improve the CKD patients' quality of life.
  • ||||||||||  calcifediol / Generic mfg.
    Review, Journal:  The "Sunshine Vitamin" and Its Antioxidant Benefits for Enhancing Muscle Function. (Pubmed Central) -  Jul 31, 2024   
    This review explores the intricate molecular mechanisms through which vitamin D modulates oxidative stress and its consequent effects on muscle function. The aim is to evaluate if vitamin D supplementation in conditions involving oxidative stress and inflammation could prevent decline and promote or maintain muscle function effectively.
  • ||||||||||  Review, Journal:  Bidirectional Relationships between Sarcopenia and Pelvic Floor Disorders. (Pubmed Central) -  Jul 31, 2024   
    Effective management requires comprehensive screening, the recognition of contributing factors, and tailored exercise regimens supported by a multidisciplinary approach. Future research should focus on longitudinal studies tracking disease progression and evaluating the efficacy of multidisciplinary care models in optimizing patient outcomes.
  • ||||||||||  Review, Journal:  Resveratrol and Vitamin D: Eclectic Molecules Promoting Mitochondrial Health in Sarcopenia. (Pubmed Central) -  Jul 31, 2024   
    This review provides an overview of the molecular mechanisms leading to skeletal muscle atrophy and summarizes recent advances in using resveratrol and vitamin D supplementation for its prevention and treatment. Understanding these molecular mechanisms and implementing combined interventions can optimize treatment outcomes, ensure muscle function recovery, and improve the quality of life for patients.
  • ||||||||||  Journal:  Diagnostic and predictive abilities of myokines in patients with heart failure. (Pubmed Central) -  Jul 31, 2024   
    However, only few myokines have been allocated to a promising tool for monitoring adverse cardiac remodeling, ischemia/hypoxia-related target-organ dysfunction, microvascular inflammation, sarcopenia/myopathy and prediction for poor clinical outcomes among patients with HF. This we concentrate on some most plausible myokines, such as myostatin, myonectin, brain-derived neurotrophic factor, muslin, fibroblast growth factor 21, irisin, leukemia inhibitory factor, developmental endothelial locus-1, interleukin-6, nerve growth factor and insulin-like growth factor-1, which are suggested to be useful biomarkers for HF development and progression.
  • ||||||||||  Journal:  Frailty Trajectories and Its Associated Factors in Japanese Older Adults. (Pubmed Central) -  Jul 31, 2024   
    Our findings from a 13-year longitudinal study identified five frailty trajectory patterns and seven associated factors for frailty trajectory. Proposed effective population-based frailty prevention strategies in each age group may contribute to effective strategies to extend healthy life expectancy in aging, aged, and super-aged communities.
  • ||||||||||  Review, Journal:  The Dual Burden of Frailty and Heart Failure. (Pubmed Central) -  Jul 31, 2024   
    Routine frailty screening should guide supportive interventions to optimize physical, cognitive, and psychosocial health. Further research on HF-specific frailty assessment tools and interventions is warranted to reduce this dual burden.
  • ||||||||||  Observational data, Journal:  Sarcopenia Prevalence and Risk Factors Among Older Adults in Bangkok, Thailand: A Cross-Sectional Study. (Pubmed Central) -  Jul 31, 2024   
    Further research on HF-specific frailty assessment tools and interventions is warranted to reduce this dual burden. This study evaluated the sarcopenia status across a diverse demographic of older Thai adults using comprehensive assessments, and examined the impact of socioeconomic factors and various chronic conditions on the occurrence of sarcopenia.
  • ||||||||||  Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  DEMAIN: Identification of Relevant Biological, Imaging, Mobility and Clinical Markers for Clinical Research in Sarcopenia (clinicaltrials.gov) -  Jul 31, 2024   
    P=N/A,  N=16, Completed, 
    Elevated levels of SII were associated with an increased risk of SO in middle-aged and elderly adults, especially in the elderly population, and elevated TyG levels played a role in this relationship. Recruiting --> Completed | N=30 --> 16 | Trial completion date: Dec 2023 --> Apr 2024 | Trial primary completion date: Dec 2023 --> Apr 2024
  • ||||||||||  Unexpected Stripes in the Herd: A Rare Case of Neuropathy and Weakness. (Exhibit Hall) -  Jul 31, 2024 - Abstract #PAINWeek2024PAINWeek_247;    
    Peripheral neuropathy and lower extremity weakness can result from a myriad of etiologies, necessitating a thorough differential diagnosis. Common causes include peripheral neuropathies such as diabetic neuropathy, Guillain-Barr
  • ||||||||||  Enrollment closed, Trial completion date, Trial primary completion date:  Effects of Low-volume HIIT Versus MICT on Physical Performance in Older Adults With Possible Sarcopenia (clinicaltrials.gov) -  Jul 30, 2024   
    P=N/A,  N=30, Active, not recruiting, 
    Common causes include peripheral neuropathies such as diabetic neuropathy, Guillain-Barr Recruiting --> Active, not recruiting | Trial completion date: May 2024 --> Oct 2024 | Trial primary completion date: Mar 2024 --> Jul 2024
  • ||||||||||  Journal:  Biological basis and treatment of frailty and sarcopenia. (Pubmed Central) -  Jul 30, 2024   
    Currently, there is no gold standard for the treatment of frailty and sarcopenia, however, growing evidence supports that a combination of exercise training and nutritional supplement improves skeletal muscle function and frailty, with a variety of other therapies being devised based on the underlying pathophysiology. In this review, we address the involvement of frailty and sarcopenia in cardiac disease and describe the latest insights into their biological mechanisms as well as the potential for intervention through exercise, diet, and specific therapies.
  • ||||||||||  Review, Journal:  The impact of sarcopenia in the treatment for patients with head and neck cancer. (Pubmed Central) -  Jul 29, 2024   
    In this case, choosing a treatment that takes sarcopenia into consideration is another way to handle it. Assessing sarcopenia prior to treatment may help avoid post-treatment pneumonia related to sarcopenia, postoperative complications including fistula, radiation-induced toxicity including swallowing disorders, and chemotherapy-related toxicity, and it is believed to greatly contribute to the prognosis of the overall survival (OS), disease-free survival (DFS), and disease-specific survival (DSS).